Table 2.

Profile of HIV-seropositive women by HAND diagnosis

	Neurocognitive Status		p
	Normal	Impaired
N	7	10
Age (years)	40.3 ± 3.0	42.0 ± 4.2	0.74
Education (years)	13.1 ± 1.1	12.7 ± 0.5	0.68
Cognitive Status
% ANI		20%
% MCMD		40%
% HAD		40%
HIV RNA viral load
log10 copies/ml
CSF (n)	2.1 ± 0.3 (7)	1.7 ± 0.1 (10)	0.38
Plasma (n)	2.7 ± 0.5 (6)	2.0 ± 0.2 (10)	0.18
CD4 (cells/mm3)	464 ± 43	831 ± 118	0.03
CD4 nadir (cells/mm3)	306 ± 61	560 ± 109	0.07
Treatment
Naïve (n)	28.6% (2)	11.1% (1)
% ART (n)	0% (0)	11.1% (1)
% HAART (n)	71.4% (5)	77.9% (7)
CPE (n)	9.0 ± 0.9 (5)	8.0 ± 1.2 (9)	0.91
YWHAE in CSF1	19.5 ± 4.6	5.7 ± 1.1	0.005
pan-14-3-3 in CSF1	15.9 ± 4.2	11.5 ± 2.7	0.56
% YWHAE heterozygotes2	14.3%	70%	0.02
Beck Depression Inventory	6.5 ± 2.4	13.1 ± 3.3	0.07
I. NPZ3	0.5 ± 0.1	−0.1 ± 0.1	0.003
II. Neuropsychological Domains/subtests
1. Frontal Executive3	0.7 ± 0.1	−0.1 ± 0.1	0.002
2. Psychomotor Speed3	0.2 ± 0.2	−0.4 ± 0.2	0.19
3. Verbal Memory3	0.4 ± 0.3	0.4 ± 0.2	0.57
4. Motor Speed3	0.7 ± 0.1	−0.1 ± 0.4	0.10

Mean ± SEM, Mann-Whitney U-test, significant difference p<0.05 in bold;

CSF = cerebral spinal fluid,

RNA = ribonucleic acid;

ANI = Asymptomatic Neurocognitive Impairment;

MCMD = Mild Cognitive Motor Disorder;

HAD = HIV-associated Dementia;

NPZ = Neurological performance z-score

¹Mean optical density of western blot expression

²z-scores,

³rs4790084(rs1204828) genotype